Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial.
Donat R Spahn, Felix Schoenrath, Gabriela H Spahn...
https://pubmed.ncbi.nlm.nih.gov/31036337/Actively Recruiting
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2026-06-02
400
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are evaluating whether a combined iron supplementation regimen can reduce the need for blood transfusions in adults with iron-deficiency anemia undergoing major elective cardiac surgery. The study compares this combined protocol to standard care to assess its safety, tolerance, and ability to lower allogeneic red blood cell transfusion during and shortly after surgery. Participants in the experimental group will receive intravenous iron sucrose 200 mg, subcutaneous recombinant human erythropoietin 150 IUkg, and intravenous vitamin C 2 g once daily for three consecutive days within the week before surgery. The control group will receive routine perioperative management based on clinical judgment. The treatment is given prior to major cardiac surgery such as coronary artery bypass grafting or valve surgery. During the study, participants will be monitored from hospital admission through 90 days after surgery. Assessments include blood transfusion volume from surgery start until five days post-surgery, changes in hemoglobin, ferritin, transferrin saturation, reticulocyte levels, quality of life, complications, mortality rates, and hospital and ICU stays. Transfusion decisions follow strict guidelines based on hemoglobin levels and signs of anemia or instability.
CONDITIONS
The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor
First Affiliated Hospital of Wenzhou Medical University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 days within the week before surgery
Participants in the experimental group receive a combined iron supplementation regimen consisting of intravenous iron sucrose, subcutaneous human erythropoietin, and intravenous vitamin C, administered once daily for three consecutive days within the week prior to surgery.
3 daily visits (in-person)
Duration - Surgery day and postoperative days 1 to 5
Participants undergo major cardiac surgery with cardiopulmonary bypass and receive standard care or the combined iron protocol as assigned. All perioperative transfusion decisions follow standardized restrictive transfusion thresholds.
Daily visits during hospital stay until postoperative day 5
Duration - Up to 90 ± 7 days after surgery
Participants are monitored after surgery including assessments at discharge, 30 ± 7 days, and 90 ± 7 days post-surgery to evaluate recovery, quality of life, and any complications.
3 visits (at discharge, ~30 days, and ~90 days post-surgery)
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Donat R Spahn, Felix Schoenrath, Gabriela H Spahn...
https://pubmed.ncbi.nlm.nih.gov/31036337/Jeffrey L Carson, Gary M Brittenham
https://pubmed.ncbi.nlm.nih.gov/36315909/Norddine Zeroual, Cinderella Blin, Marine Saour...
https://pubmed.ncbi.nlm.nih.gov/33475735/A J Fowler, T Ahmad, T E F Abbott...
https://pubmed.ncbi.nlm.nih.gov/30442249/Nizar Attallah, Yahya Osman-Malik, Stan Frinak...
https://pubmed.ncbi.nlm.nih.gov/16564942/Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor
First Affiliated Hospital of Wenzhou Medical University
Collaborating Sponsor